Tri Locum Partners LP Altimmune, Inc. Transaction History

Tri Locum Partners LP

  • $374 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$4.19 - $16.83 $851,072 - $3.42 Million
203,120 Added 62.37%
528,814 $2.23 Million
Q4 2022

Feb 14, 2023
BUY
$8.74 - $16.45 $1.47 Million - $2.77 Million
168,391 Added 107.05%
325,694 $5.36 Million
Q3 2022

Nov 14, 2022
SELL
$10.67 - $22.41 $4.45 Million - $9.35 Million
-417,343 Reduced 72.63%
157,303 $2.01 Million
Q2 2022

Aug 15, 2022
BUY
$3.94 - $11.77 $2.26 Million - $6.76 Million
574,646 New
574,646 $6.72 Million

Others Institutions Holding ALT

# of Institutions
186
Shares Held
39.3M
Call Options Held
913K
Put Options Held
743K
View Full List

About Altimmune, Inc.

ALT Quotes by TradingView
  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Tri Locum Partners LP Portfolio

Follow Tri Locum Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email